标签归档 南京新茶外卖论坛

Notice on recommending the use of traditional Chinese medicine to prevent COVID-19 in enterprises and institutions that have resumed work and production.

Prevention and control of pneumonia in novel coronavirus by cities and counties (districts) emergency headquarters;

In order to implement the provincial government’s Notice on Strengthening the Scientific Prevention and Control of Epidemic Situation and Promoting the Resumption of Production of Enterprises in the Province and the No.14 Order of emergency headquarters Province on Epidemic Prevention and Control, and give full play to the core role of traditional Chinese medicine in disease prevention, the Provincial Administration of Traditional Chinese Medicine organized experts from Jiangxi University of Traditional Chinese Medicine and other units to study and formulate a prescription of traditional Chinese medicine for preventing COVID-19 for employees of enterprises and institutions that have resumed work and resumed production on the basis of summarizing the preventive drugs used in our province in the early stage. Now, the prescriptions of traditional Chinese medicine for employees of enterprises and institutions who have resumed production to prevent COVID-19 are recommended for reference.

First, the general population prevention prescription

10g of atractylodes rhizome, 5g of dried tangerine peel, 5g of agastache rugosa, 5g of perilla, 5g of honeysuckle, 5g of cyrtomium rhizome and 10g of raw astragalus root.

Function: Aromatic turbidity, clearing away heat and toxic materials, and consolidating exterior.

Second, the prescription for the prevention of the weak population

15g of Radix Astragali, 10g of Radix Saposhnikoviae, 10g of Rhizoma Atractylodis Macrocephalae, 5g of Herba Agastaches, 5g of Perillae and 5g of Flos Lonicerae.

Function: invigorating qi, consolidating exterior, aromatic and turbid, and clearing away heat and toxic materials.

Prevention and Control of Pneumonia Infected in novel coronavirus Province

Emergency headquarters office

February 21, 2020

Notice on printing and distributing the prevention and control scheme of traditional Chinese medicine in novel coronavirus, Jiangxi Province (Trial Third Edition)

The health committees of counties (cities) directly under the jurisdiction of all districts and cities, and relevant medical institutions directly under the jurisdiction of the province:

In order to give full play to the unique role of traditional Chinese medicine in the prevention and treatment of novel coronavirus epidemic, according to the Notice of the General Office of the National Health and Wellness Committee and the Office of state administration of traditional chinese medicine on Printing and Distributing the Diagnosis and Treatment Plan of novel coronavirus (Trial Sixth Edition) (Guo Wei Ban Yi Han [2020] No.145), we organized experts to analyze and summarize the prevention and treatment of novel coronavirus by traditional Chinese medicine in our province, and combined with the geographical and climatic characteristics of Jiangxi, revised the prevention and treatment plan of traditional Chinese medicine, and formed the "Prevention and Treatment of Traditional Chinese Medicine in novel coronavirus, Jiangxi Province" Is issued to you, please refer to the implementation.

Attachment: Prevention and Treatment Plan of Traditional Chinese Medicine in novel coronavirus, Jiangxi Province (Trial Third Edition)

Jiangxi provincial administration of traditional Chinese medicine

February 21, 2020

Prevention and treatment scheme of traditional Chinese medicine in novel coronavirus, Jiangxi Province

(Trial Third Edition)

In order to give full play to the role of Chinese medicine in the prevention and control of epidemic situation in novel coronavirus, combined with the situation of Chinese medicine participating in the treatment of early confirmed cases in our province and the regional and climatic characteristics, and further improve the prevention and syndrome differentiation treatment of novel coronavirus by Chinese medicine, this scheme is formulated.

I. Characteristics of the disease

(1) Clinical manifestations

Based on the current epidemiological investigation, the incubation period is 1-14 days, mostly 3-7 days. The main manifestations are fever, dry cough and fatigue. A few patients have symptoms such as nasal congestion, runny nose, sore throat, myalgia and diarrhea. Severe patients often have dyspnea and/or hypoxemia one week after onset, and severe patients can rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis that is difficult to correct, bleeding and coagulation dysfunction and multiple organ failure. It is worth noting that severe and critical patients may have moderate to low fever or even no obvious fever during the course of the disease.

Mild patients only showed low fever, slight fatigue, etc., and no pneumonia.

Judging from the current cases, most patients have a good prognosis and a few patients are in critical condition. The prognosis of the elderly and those with chronic basic diseases is poor. The symptoms of children cases are relatively mild.

(2) Laboratory inspection

At the early stage of onset, the total number of white blood cells in peripheral blood is normal or decreased, and the lymphocyte count is decreased. Some patients may have increased liver enzymes, lactate dehydrogenase (LDH), muscle enzymes and myoglobin. Increased troponin can be seen in some critically ill patients. C-reactive protein (CRP) and erythrocyte sedimentation rate increased in most patients, and procalcitonin was normal. In severe cases, D- dimer increased and peripheral blood lymphocytes decreased progressively. Severe and critical patients often have elevated inflammatory factors.

Novel coronavirus nucleic acid can be detected in nasopharyngeal swab, sputum and other lower respiratory secretions, blood, feces and other samples.

In order to improve the positive rate of nucleic acid detection, it is suggested that sputum should be collected as much as possible, and lower respiratory tract secretions should be collected by patients undergoing tracheal intubation, and the samples should be sent for inspection as soon as possible after collection.

(3) Chest imaging

In the early stage, there were many small patches and interstitial changes, especially in the outer lung. Then it develops into multiple ground glass shadows and infiltration shadows in both lungs. In severe cases, lung consolidation can occur, and pleural effusion is rare.

Second, prevention of traditional Chinese medicine

(1) Drug prevention

1. Tea substitute: Radix Pseudostellariae 3g, Flos Lonicerae 3g, Herba Agastaches 3g, Radix Platycodi 3g, and Radix Glycyrrhizae 3g.

2. Basic prescription: Yupingfeng Powder, which consists of raw astragalus root 12g, Saposhnikovia root 10g, Atractylodes macrocephala 10g, Lonicera japonica 10g, Forsythia suspensa 10g, Rhizoma Osmundae 6g, Eupatorium odoratum 10g, Pericarpium Citri Tangerinae 10g, Rhizoma Atractylodis 10g and Radix Platycodi 10g.

(2) Prevention of Heat-sensitive Moxibustion (One Ai and Three Uses)

(1) Smell mugwort

Smell the Ai Xiang produced by heat-sensitive moxibustion moxa sticks several times a day for 30 seconds each time. The aromatic components of pure moxa in heat-sensitive moxibustion moxa sticks and the aromatic medicinal properties of Notopterygium Rhizoma, Radix Angelicae Pubescentis, Herba Asari and Rhizoma Ligustici Chuanxiong have good functions of refreshing the brain, sensitizing the sense of smell, purifying the internal environment of the nasopharynx and improving the immunity of the nasopharynx. Smelling the fragrance can not only publicize the pathogenic factors of upper energizer and dampness, but also prevent the exogenous pathogenic factors.

(2) moxibustion

Selection of points: Zhongwan, Shenque and Guanyuan.

Operation method: hanging moxibustion back and forth along meridian. During moxibustion, the moxa heat moves slowly near the moxibustion point, finding the position where the heat has special feelings such as penetration, distant transmission, diffusion and comfort, and carrying out moxibustion back and forth along the meridian.

Moxibustion amount: once a day, each point is moxibustion for about 45 minutes.

On the basis of the above, those who can accept wheat grain moxibustion add wheat grain moxibustion to Zusanli point, and the effect is better.

Precautions: During moxibustion, the moxibustion recipient should pay attention to cold and warmth, and keep the room temperature at about 25 degrees; It is not advisable to take a bath within 4 hours after moxibustion.

(3) Ai pedicure

Soak your feet with half a stick of moxa stick with heat-sensitive moxibustion in 1000 ml of hot water for 30 minutes every day until the skin on your forehead or nape is moist or slightly sweaty.

This scheme has three uses. The application of dynamic moxibustion can effectively stimulate the movement of menstruation and qi, mobilize the body’s own regulatory function, eliminate dampness and transport the spleen; Cooperate with wheat grain moxibustion to improve human immunity and strengthen the body; Sensitize the sense of smell through the aromatic smell, and publicize the pathogenic factors of upper energizer and dampness; Using hot Folium Artemisiae Argyi water, the meridians of lower limbs are warmed, and the coking is wet and turbid. Treating the triple energizer with the same treatment, giving consideration to both the symptoms and the root causes, has obvious effects of aromatization and dampness elimination, and announces the triple energizer.

Third, Chinese medicine treatment

This disease belongs to the category of "epidemic" disease in traditional Chinese medicine. Because of the feeling of "epidemic", all localities can treat it according to the condition, local climate characteristics and different constitutions, with reference to the following schemes. Doses exceeding pharmacopoeia should be used under the guidance of doctors.

1. Medical observation period

Clinical manifestation 1: fatigue with gastrointestinal discomfort

Recommended Chinese patent medicine: Huoxiang Zhengqi Capsule (pill, water, oral liquid)

Clinical manifestation 2: fatigue with fever

Recommended Chinese patent medicines: Jinhua Qinggan granules, Lianhua Qingwen capsules (granules), Shufeng Jiedu capsules (granules) and Chimonanthus chinensis leaves granules.

2. Clinical treatment period (confirmed cases)

2.1 Qingfei Paidu Decoction

Scope of application: it is suitable for light, ordinary and severe patients, and can be used reasonably in combination with the actual situation of patients in the treatment of critical patients.

Basic prescription: Herba Ephedrae 9g, Radix Glycyrrhizae Preparata 6g, Semen Armeniacae Amarum 9g, Gypsum Fibrosum 15?30g (decocted first), Ramulus Cinnamomi 9g, Rhizoma Alismatis 9g, Polyporus 9g, Atractylodis Macrocephalae 9g, Poria 15g, Radix Bupleuri 16g, Scutellariae 6g, Jiang Banxia 9g, Rhizoma Zingiberis Recens 9g, Radix Asteris 9g, Flos Lonicerae 9g, Rhizoma Belamcandae 9g, Herba Asari 6g, Rhizoma Dioscoreae 12g, Fructus Aurantii Immatur

Administration method: traditional Chinese medicine decoction pieces, decocted in water. One dose a day, twice in the morning and evening (40 minutes after meals), and three doses for a course of treatment.

If conditions permit, you can take half a bowl of rice soup after taking the medicine every time, and you can take an extra bowl for those with dry tongue and body fluid deficiency. (Note: If the patient has no fever, the dosage of gypsum should be small, and the dosage of gypsum can be increased if the patient has fever or strong heat). If the symptoms improve but are not cured, take the second course of treatment. If the patient has special circumstances or other basic diseases, the prescription can be modified according to the actual situation in the second course of treatment, and the drug will be stopped when the symptoms disappear.

Source of prescription: Notice of the General Office of the National Health and Wellness Commission and the Office of state administration of traditional chinese medicine on Recommending the Use of Qingfei Paidu Decoction in the Treatment of Pneumonia Infected by novel coronavirus with Integrated Traditional Chinese and Western Medicine (No.22 [2020] of the Office of Traditional Chinese Medicine).

2.2 heat-sensitive moxibustion treatment

Scope of application: it is suitable for mild, common, clinical observation period and recovery period of lung and spleen deficiency syndrome.

Therapeutic effect: benefiting the temperature and spleen, aromatic and dampness.

2.2.1 Moxibustion points: Shenque, Tian Shu (double) and Daheng (double).

2.2.2 Posture: Take a comfortable supine position and relax the whole body.

2.2.3 Operation:

The moxibustion victim lies on his back, respectively ignites two sections of moxa sticks with a diameter of 2.5 cm and a length of 4cm, and inserts them into a special moxibustion device with an moxa heat reflecting cavity and capable of adjusting the unit heat, wherein the moxibustion device is 22 cm long and 16 cm wide, and the smoke outlet of the moxibustion device is connected with a portable smoke eliminator, and the moxibustion device is placed horizontally with the navel as the center. In the process of moxibustion, the intensity of moxa heat can be adjusted by adjusting the handle of each moxibustion unit, so that the abdominal acupoint area of moxibustion feels hot, uniform, comfortable and not burning. By moving the moxibustion tool up and down, left and right on the navel, we can find the position where the heat sensation is permeated, spread, diffused and comfortable, and then let it stand for moxibustion. During the whole moxibustion process, it is necessary to ensure that the heat is uniform, comfortable and not burning, and the heat-sensitive induction such as deep heat, distal heat, body drying heat and forehead sweating subsides to a certain degree.

2.2.4 Moxibustion amount: once a day, about 40 to 60 minutes, and each moxibustion should not exceed 60 minutes.

2.3 light

(1) Cold-dampness stagnation of lung syndrome

Clinical manifestations: fever, fatigue, body aches, cough, expectoration, chest tightness, anorexia, nausea, vomiting, and sticky stool. The tongue is light, fat, with teeth marks or reddish, and the coating is white, thick, rotten or white, with moist or slippery pulse.

Recommended prescription: Dispelling cold, removing dampness and resisting toxin.

Raw Herba Ephedrae 6g, almond 9g, Ramulus Cinnamomi 9g, Radix Glycyrrhizae Preparata 6g, fried atractylodes 9g, Perilla 6g, Rhizoma Pinelliae Preparata 9g, Pericarpium Citri Tangerinae 9g, Radix Peucedani 9g, Radix Platycodi 9g, Fructus Aurantii 9g, Poria 9g, Ginger 9g and Jujube 9g.

For those with cold and heat, 9g of Bupleurum and 9 g of Scutellaria baicalensis Georgi are added; For those with obvious vomiting and diarrhea, Huoxiang Zhengqi Powder is used.

Administration method: 1 dose per day, 400ml decoction, taken twice, once in the morning and once in the evening, before meals.

(2) Syndrome of damp-heat accumulating in lung

Clinical manifestations: low or no fever, slight aversion to cold, fatigue, heavy head and body drowsiness, muscle aches, dry expectoration, sore throat, dry mouth and no desire to drink more, or accompanied by chest tightness, anorexia, loose stool or sticky stool. The tongue is reddish, the coating is white, thick and greasy or thin and yellow, and the pulse is slippery or moist.

Recommended prescription: Qingre Huashi Antitoxic Formula

Semen Armeniacae Amarum 9g, Scutellariae Radix 9g, Fructus Forsythiae 9g, Poria 9g, Fructus Amomi Rotundus 6g (bottom), Talcum 9g (fried), Folium Mori 9g, Herba Ephedrae 6g, Semen Coicis 15g, and Radix Glycyrrhizae 6g.

Bitter mouth, nausea and vomiting, combined with Xiaochaihu decoction; Nausea and nausea with joint pain, combined with Chaihu Guizhi decoction; Asthma, chest tightness, combined with "Xuanbi Decoction" in Treatise on Epidemic Febrile Diseases.

Administration method: 1 dose per day, 400ml decoction, taken twice, once in the morning and once in the evening.

2.4 Ordinary type

(1) Damp-toxic stagnation of lung syndrome

Clinical manifestations: fever, cough with little phlegm, or yellow phlegm, shortness of breath, abdominal distension and constipation. The tongue is dark red, the tongue is fat, the coating is yellow and greasy or yellow and dry, and the pulse is slippery or stringy.

Recommended prescription: Modified Qingre Huashi Antitoxic Formula

Semen Armeniacae Amarum 9g, Scutellariae Radix 9g, Fructus Forsythiae 9g, Poria 9g, Fructus Amomi Rotundus 6g (bottom), Talcum 9g (fried), Folium Mori 9g, Rhizoma Phragmitis 9g, Semen Benincasae 9g, Semen Persicae 6g, and Semen Coicis 15g.

For patients with mild diarrhea, 9 g of Radix Puerariae is added; Cough with yellow phlegm, add 9g of buckwheat and 9 g of houttuynia cordata; Cough and rest, don’t lie down, and combine the jujube and xiefei decoction; Throat blocking sore throat, combined with Yinqiao Mabo powder.

Administration method: 1 dose per day, 400ml decoction, taken twice, once in the morning and once in the evening.

(2) Cold-dampness blocking lung syndrome

Clinical manifestations: low fever, low body heat, or no fever, dry cough, less phlegm, fatigue, chest tightness, fullness, or nausea, loose stool. The tongue is pale or reddish, with white or greasy fur and moist pulse.

Recommended prescription: Modified formula for dispelling cold, removing dampness and resisting toxin.

Raw Herba Ephedrae 6g, almond 9g, cassia twig 9g, Radix Glycyrrhizae Preparata 6g, fried atractylodes 9g, Herba Agastaches 9g, Magnolia Officinalis 9g, Poria 9g, Pericarpium Citri Tangerinae 9g, Massa Medicata Fermentata 9g, stir-fried malt 9g, Pericarpium Arecae 6g, Herba Artemisiae Scopariae 6g and Bupleuri 9g.

Thirsty, cough phlegm is not easy to come out, add gypsum 915 g; Cough leads to chest pain, combined with Qianjin Weijing Decoction.

Administration method: 1 dose per day, 400ml decoction, taken twice, once in the morning and once in the evening.

2.5 heavy duty

(1) Syndrome of lung-closing due to epidemic toxin

Clinical manifestations: red fever, cough, yellow sticky sputum, or blood in sputum, shortness of breath, fatigue, dry mouth, nausea, poor stool, short and red urine. Red tongue, yellow greasy fur, and slippery pulse.

Recommended prescription: 6g of raw ephedra, 9g of almond, 15g of gypsum Fibrosum, 3g of licorice, 10g of Pogostemon Pogostemonis (lower back), 10g of Magnolia officinalis, 15g of Atractylodes lancea, 10g of Amomum tsaoko, 9g of Rhizoma Pinelliae Preparata, 15g of Poria, 5g of raw rhubarb (lower back), 10g of raw Astragalus, 10g of Lepidium Seed and 10g of Paeonia Rubra.

9g of cogongrass rhizome is added for those with obvious blood in sputum.

Administration: 12 doses a day, decocted in water, 100 ml and 200 ml each time, 24 times a day, orally or by nasal feeding.

(2) gas camp two burnt certificates

Clinical manifestations: fever, polydipsia, shortness of breath, delirium, wrong vision, or rash, or vomiting blood, epistaxis, or limb convulsions. The tongue is crimson with little or no coating, and the pulse is heavy and thin, or it is large and numerous.

Recommended prescription: Gypsum Fibrosum 3060g (fried first), Anemarrhena asphodeloides 30g, Radix Rehmanniae 3060g, Cornu Bubali 30g (fried first), Radix Paeoniae Rubra 30g, Radix Scrophulariae 30g, Fructus Forsythiae 15g, Cortex Moutan 15g, Rhizoma Coptidis 6g, Folium Bambusae 12g, Semen Lepidii 15g and Radix Glycyrrhizae 6g.

Administration method: 1 dose per day, decocted with water, first decocted with gypsum and buffalo horn, 100 ml and 200 ml each time, 24 times a day, orally or by nasal feeding.

Recommended Chinese patent medicines: Xiyanping injection, Xuebijing injection, Reduning injection, Tanreqing injection and Xingnaojing injection. Drugs with similar efficacy can be selected according to individual conditions, or they can be used in combination according to clinical symptoms. Traditional Chinese medicine injection can be used in combination with traditional Chinese medicine decoction.

2.6 Critical type (syndrome of internal closure and external detachment)

Clinical manifestations: dyspnea, frequent wheezing or mechanical ventilation, dizziness, dysphoria, sweating with cold limbs, dark purple tongue, thick greasy or dry fur, floating pulse without roots.

Recommended prescription: 15g of Ginseng, 10g of Heishun Tablet (fried first) and 15g of Cornus officinalis. Take Suhexiang Pill or Angong Niuhuang Pill.

Recommended Chinese patent medicines: Xuebijing injection, Reduning injection, Tanreqing injection, Xingnaojing injection, Shenfu injection, Shengmai injection and Shenmai injection. Drugs with similar efficacy can be selected according to individual conditions, or they can be used in combination according to clinical symptoms. Traditional Chinese medicine injection can be used in combination with traditional Chinese medicine decoction.

Note: Recommended usage of heavy and critical traditional Chinese medicine injections.

The use of traditional Chinese medicine injections follows the principle of small dosage and gradual dialectical adjustment in the drug instructions. The recommended usage is as follows:

Virus infection or mild bacterial infection: 0.9% sodium chloride injection 250ml plus Xiyanping injection 100mg bid, or 0.9% sodium chloride injection 250ml plus Reduning injection 20ml, or 0.9% sodium chloride injection 250ml plus Tanreqing injection 40ml bid.

High fever with disturbance of consciousness: 250ml of 0.9% sodium chloride injection and 20 ml of Xingnaojing injection bid.

Systemic inflammatory response syndrome or/and multiple organ failure: 250ml of 0.9% sodium chloride injection and 100 ml of Xuebijing injection.

Immunosuppression: 250ml of 0.9% sodium chloride injection and 100ml bid of Shenmai injection.

Shock: 250ml of 0.9% sodium chloride injection and 100ml bid of Shenfu injection.

2.7 recovery period

(1) Deficiency of lung and spleen-qi syndrome

Clinical manifestations: shortness of breath, fatigue, anorexia, nausea, fullness, weak stool and loose stool’s discomfort. The tongue is pale and fat, and the coating is white and greasy.

Recommended prescription: Rhizoma Pinelliae Preparata 9g, Pericarpium Citri Tangerinae 10g, Radix Codonopsis 15g, Radix Astragali Preparata 30g, fried atractylodes 10g, Poria 15g, Herba Agastaches 10g, Fructus Amomi 6g (below) and Radix Glycyrrhizae 6g.

Administration method: 1 dose per day, 400ml decoction, taken twice, once in the morning and once in the evening.

Recommended Chinese patent medicines: Shenling Baizhu Powder and Xiangsha Liujun Pill.

Adjuvant dietotherapy: the monkey in the river is thin with rice.

(2) Deficiency of both Qi and Yin

Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitation, excessive sweating, anorexia, low or moderate fever, dry cough and little phlegm. The tongue is dry with little body fluid, and the pulse is thin or weak.

Recommended prescription: 10g Radix Adenophorae, 10g Radix Ophiopogonis, 6g Radix Panacis Quinquefolii, 6g Fructus Schisandrae Chinensis, 15g Gypsum Fibrosum, 10g Folium Bambusae, 10g Folium Mori, 15g Rhizoma Phragmitis, 15g Radix Salviae Miltiorrhizae and 6g Radix Glycyrrhizae.

Administration method: 1 dose per day, 400ml decoction, taken twice, once in the morning and once in the evening.

(3) yang deficiency, phlegm and blood stasis syndrome

Clinical manifestations: chest tightness and suffocation, shortness of breath when moving, paroxysmal dry cough and choking cough, or coughing a small amount of white phlegm, white face and fear of cold. The tongue is dull, the coating is thin, white or greasy, and the pulse is heavy or astringent.

Chest CT showed obvious signs of pulmonary interstitial lesions.

Recommended prescription: Warming Lung and Chemical Fiber Decoction

15g of cornu Cervi Degelatinatum, 4g of Cinnamomum cassia, 10g of Rhizoma Zingiberis Preparata, 10g of Herba Ephedrae, 20g of Radix Rehmanniae Preparata, 10g of Semen Sinapis Albae, 6g of Radix Glycyrrhizae Preparata, 10g of Lumbricus, 10g of Eupolyphaga Seu Steleophaga, 10g of Rhizoma Chuanxiong, 10g of Semen Persicae and 10g of Carthami Flos.

15g of stir-fried malt and 15g of stir-fried rice buds are added to those who accept the poor; If qi deficiency is prominent, such as shortness of breath, mental fatigue and laziness, Buzhong Yiqi Decoction should be combined; People with yin deficiency such as dry mouth, dry throat, less fur, etc., combined with Shengmai drink; For patients with obvious cough, add 10g of Radix Asteris, 10g of Flos Farfarae, 10g of Stemonae and 10g of Perilla.

Administration method: 1 dose per day, 400ml decoction, taken twice, once in the morning and once in the evening.

Recommended Chinese patent medicine: Jinshuibao capsule (tablet)

Source: Provincial Administration of Traditional Chinese Medicine and Jiangxi Provincial Hospital of Traditional Chinese Medicine.

Nanchang release

Wechat WeChat official account: nc_fabu

Original title: "Authoritative release! The recommended Chinese medicine prescription for preventing COVID-19 is coming! Get out of here "

　　This year, Fujian Province Tendering and Purchasing Group Co., Ltd. witnessed great events and good deeds.

　　Brand, won the annual top ten brands of China tendering agency, the top 100 consulting service agencies of China PPP project, and the national advanced productivity model enterprise award; In the main business, the provincial environmental protection design institute, the design institute of the University of Technology and the consulting supervision of the University of Technology have become a member of the group in different forms, such as capital increase and holding, decoupling and transfer, and are moving towards a comprehensive technical service group; Strategically, high-tech industrialization projects such as large-capacity solid-state lithium batteries, intelligent robots and three-dimensional codes, which have invested or participated in, are progressing smoothly, making a good start for a new round of transformation and development; In terms of capital operation, Fujian Tendering Co., Ltd. was formally established, and the "6 18" industrial equity investment fund entered operation …

　　In the structural reform of the supply side, the provincial bidding group has formed a trend of "double highs" of high-end service industry and high-tech industry. "In the face of the new normal of economic development, with the guidance and support of the provincial SASAC, we focus on developing three major sectors of business. While providing excellent engineering and technical consulting services, we integrate resources to invest in new formats such as modern logistics parks, and rely on the’ 6 18′ platform to develop high-tech industries." Chen Wu, Party Secretary and Chairman of the Group, summed up the development ideas of the Group.

　　Seize the opportunity to create new advantages in the main business

　　In mid-October this year, 20 departments, including the Ministry of Finance and the Ministry of Education, jointly announced the third batch of government-social capital cooperation (PPP) demonstration projects, and 25 projects in Fujian Province were listed, 15 of which were consulted by Fujian Provincial Bidding and Purchasing Group. It is no accident that this achievement was achieved.

　　Fujian tendering and purchasing group was formerly known as Fuzhou mechanical and electrical equipment tendering company, which was established in 1988. In 1990, it became the institution directly under the former Provincial Economic and Trade Commission. In 1992, it was renamed as Fujian mechanical and electrical equipment tendering company. In 2010, it was restructured with the approval of the provincial government and became the only technical service group enterprise among provincial state-owned enterprises.

　　Over the years, the Provincial Tendering and Purchasing Group has kept up with the new development direction of the industry, constantly improved the industrial chain of engineering technical consulting services, and formed business sectors such as engineering consulting, tendering agency, cost consulting, project agent construction, engineering supervision, engineering design, test and geographical mapping, etc. It has obvious advantages in technical consulting services such as bidding, and its business scale and economic benefits have always been among the best in the technical consulting industry of engineering construction projects in China.

　　"The 18th National Congress of the Communist Party of China proposed that the market should play a decisive role in resource allocation, and the PPP model has become an important measure for the reform of investment and financing systems in various places. We promptly deployed excellent teams and set up PPP consulting centers, becoming the first batch of warehousing PPP consulting institutions in Fujian Province, providing project owners with consulting services in the whole process, such as preliminary preparation, investment selection and social capital, negotiation and assistance in signing agreements. " Chen Wu said.

　　The Provincial Tendering Group has also developed and built an electronic tendering and purchasing platform in combination with "internet plus" to help the work of the national electronic tendering and bidding innovation pilot province in our province. The platform for purchasing bulk materials, the exhibition platform for state-owned enterprises and private enterprises, and the 6.18 "Double Creation" cloud platform are being gradually popularized and applied with the support of relevant departments. With the help of "internet plus", the Group has continuously broadened the breadth and depth of services, vigorously developed high-end services throughout the process, and changed to professional and consulting services, effectively upgrading the main business of existing technical consulting services.

　　Break through the new format of orderly layout in change

　　On December 2nd, at the "2016′ Sky Map Fujian’ Achievement Application Promotion Conference" hosted by the Provincial Basic Geographic Information Center, Fujian Jingwei Surveying and Mapping Information Co., Ltd. proposed a complete solution based on the UAV’s’ Sky Map Fujian’ small area image rapid update mechanism, which aroused great interest of the docking party.

　　In the information age, data is king. Jingwei Surveying and Mapping Company, an enterprise owned by Provincial Tendering Group, got rid of the shackles of traditional surveying and mapping, made great efforts to tap the socialized application of surveying and mapping geographic information industry, further expanded the application of surveying and mapping geographic information in smart cities, smart transportation, smart tourism and other industries, and actively created consumer goods based on surveying and mapping information, such as food, clothing, housing and transportation, which served the public, and achieved fruitful results.

　　In recent years, in the process of integration and reorganization, the provincial bidding group has repeatedly made moves to integrate resources from all sides, create new advantages and lay out new formats.

　　With the transfer of Provincial Traffic Construction Engineering Supervision Consulting Co., Ltd., Provincial Road Port Engineering Consulting Co., Ltd. and Provincial Traffic Construction Engineering Test and Detection Co., Ltd. into wholly-owned subsidiaries, the Group has increased investment in high-end equipment and consolidated the authority and leading advantages of these companies in traffic engineering related fields in our province. In September last year, Provincial Traffic Construction Engineering Test and Testing Co., Ltd. passed the national laboratory accreditation qualification evaluation. In June this year, the provincial and local standard "Technical Specification for Inspection and Evaluation of Prestressed Construction Quality of Highway Engineering Concrete Bridges" edited by the company passed the examination and approval of the Provincial Bureau of Quality and Technical Supervision, filling the gap in our province; In November, two provincial and local standards, "Technical Specification for Testing Compactness of Road Fill Subgrade by Electromagnetic Method" and "Technical Specification for Installation and Replacement of Bridge Bearings", were reviewed and approved.

　　While laying a solid foundation, the Group is building an experimental testing base in Pushang Industrial Zone, Jinshan, Fuzhou, which provides good conditions for the development of testing business to be specialized, sophisticated and sophisticated. While investing in the establishment of Fujian Intelligent Maintenance Engineering Co., Ltd., it will integrate the superior resources of all ownership enterprises and apply big data to develop businesses focusing on health inspection and intelligent maintenance of roads and bridges.

　　The provincial tendering group also cooperated with Putian Jiaotou Group to develop the logistics park project of Putian train freight station area. While providing comprehensive project development consultation and construction management, Fujian Minzhao Logistics Park Construction and Development Co., Ltd. will be jointly funded to carry out unified planning, investment, financing, construction and management of park projects, and introduce social capital investment or organize logistics enterprises to participate in investment and development. This project, with a total investment of 5.8 billion yuan, plans to build five parks, namely, e-commerce logistics zone, multimodal transport logistics zone, smart logistics industrial zone, commerce logistics zone and bulk cargo logistics zone, which will be built into a demonstration industrial park in Putian City, integrating e-commerce and its supporting facilities, interacting with the sales, distribution, warehousing and trade of products in surrounding industrial parks, forming a seamless connection with physical stores, and creating a new format of modern logistics construction and operation.

　　In addition, this year, it also signed a strategic cooperation framework agreement with Ningde Urban Construction Group, which will carry out all-round cooperation in project management, engineering consulting services and investment and development of new logistics platforms.

　　Keep a close eye on "6 18" and cultivate new growth points

　　Recently, Fujian Judian New Energy Co., Ltd., a holding subsidiary of the bidding group, completed the bidding for the renovation project of the comprehensive office building, and is preparing to start related projects. The company introduced the patented technology of "Large-capacity solid-state power lithium battery" from Beijing Shenzhou Judian, implemented industrialization in Wuyi New District, and will produce large-capacity polymer lithium-ion batteries by stages.

　　Marching into high-tech industries, the provincial bidding group is taking solid steps.

　　In 2015, the provincial government decided to hand over the market-oriented operation function of the China Strait Project Fair (referred to as "6 18"), which has been successfully held for more than ten sessions, and approved the group to initiate the establishment of the "6 18" industrial equity investment fund to carry out the incubation and industrialization of the "6 18" docking project.

　　Seize the opportunity of docking cutting-edge scientific and technological achievements, the provincial tendering group has successively invested and established Fujian 618 Industrial Development Co., Ltd., Minzhao Industrial Investment Fund Management Co., Ltd., 618 Information Technology Co., Ltd. and other ownership companies.

　　This year, "6 18" was operated by the group for the first time. According to the work arrangement of the provincial party committee and government, closely centering on the "June 18th" strategic plan, and under the guidance of the provincial development and reform commission, the provincial tendering group promoted all the work with the concept of "government guidance, market-oriented operation and professional management" and achieved good results.

　　The Group also organized professional teams to actively search for high-tech projects in line with the national and provincial key industrial policies through the "6 18" platform. On the one hand, the "6.18" industrial equity investment fund will drive more social capital to participate in the incubation and industrialization of the "6.18" docking project and strengthen the transformation effect of the "6.18" project; On the other hand, it directly participates in the landing industrialization of some projects by means of equity investment, laying the foundation for the development of high-tech industries.

　　"Large-capacity solid-state power lithium battery" is the exhibition project of "June 18th" this year. On June 21st, the tendering group signed an investment intention cooperation agreement with the project and the three-dimensional code project. At present, the project has basically completed the preliminary work and is preparing to start construction, while the three-dimensional code project is also progressing in an orderly manner and the investment will be completed in the near future. In addition, after the "6 18" exhibition, the bidding group also actively docked with Haixi Research Institute of Chinese Academy of Sciences and reached cooperation intentions on six-axis joint robots and other projects.

　　"While running’ 6 18′ well, relying on this innovative platform, we will seize the link of transformation and industrialization of scientific and technological achievements, promote the transformation and upgrading of’ 6 18′, and at the same time invest in a number of high-tech transformation projects, making it a new growth point and the focus of transformation and upgrading of the Group." Chen Wu said.

Source | A drug Buff

In December 2021, Pfizer COVID-19 took the medicine orally. Paxlovid Obtain FDA emergency use authorization.

In February 2022,Paxlovid It was approved by emergency conditions in National Medical Products Administration, China, and then it was written into the latest diagnosis and treatment plan.

Paxlovid It has been approved for listing in more than 50 countries around the world.

but Paxlovid　Its use in the real world is full of controversy.

"I thank the pharmaceutical companies for providing patients with effective COVID-19 therapy. But I am also frustrated that these companies seem to be in complete control of the situation, and I believe that Americans can get more benefits from pharmaceutical giants as long as our regulators dare to ask. Paxlovid was approved based on a study that seems to exaggerate the benefits that most Americans can get from this drug, rather than providing us with more information about it. " This is a primary care doctor at Weill Cornell Medical College in new york when talking about Covid-19’s therapeutic drugs. Paul Fenyves Some feelings.

Among the antiviral drugs in COVID-19, Pfizer’s Paxlovid Has become an obvious winner for two reasons:

Firstly, compared with monoclonal antibodies and Remdesivir, Paxlovid, as a pill, is easier to administer.

Secondly, Paxlovid seems to be very effective. A clinical trial shows that,Hospitalization or death of high-risk patients who received treatment decreased by 89%..

It seems to be very effective because there is a problem: FDA’s emergency use authorization (EUA) for Paxlovid is only based on the data of a single trial, and the trial only includes people who have never been vaccinated with COVID-19 vaccine before. At present, 76% of American adults have been vaccinated with COVID-19 vaccine, and it is estimated that 58% of Americans have been infected with Covid-19, so the experiment supporting Paxlovid EUA is not directly applicable to most Americans.

This means that doctors who treat patients with COVID-19 do not know to what extent (if any) Paxlovid can benefit patients who have been vaccinated. Doctors only have hope and speculation, and continue to prescribe Paxlovid to high-risk patients in COVID-19, but they are not sure whether they are really helping them.

Paxlovid Generic has been authorized in 95 countries.

History seems familiar.

Paxlovid’s current situation is reminiscent of previous antiviral drugs.oseltamivirIt was also controversial during the outbreak of swine flu.

Influenza kills an average of 40,000 Americans and hundreds of thousands of people around the world every year, so everyone is trying to develop antiviral drugs that can reduce its severity. Roche first introduced it in 1999.oseltamivir (oseltamivir), it is such a drug. Clinical studies reported by Roche show that existing evidence shows that Tamiflu reduces the risk of pneumonia, which is a common and important complication of influenza. For many years, doctors’ impression of using Tamiflu is that it reduces the risk of serious diseases.

Tamiflu (oseltamivir phosphate capsule) is indicated for the treatment of influenza A and B in adults and children over one year old. Patients should use it within 48 hours of the first symptom.

Tamiflu was included in the list of essential drugs by WHO. During the influenza outbreak in 2009, governments all over the world spent a lot of money to reserve a lot of Tamiflu to protect their citizens, because its manufacturer said, "Trust us, it works!" .

The Cochrane Collaboration made a meta-analysis of the clinical trial data of oseltamivir (Tamiflu) and zanamivir (Legonqing of GSK) and all published literature research results, and formed a comprehensive report, which was published in the British Medical Journal (BMJ) on April 10th, 2014.

The report pointed out that, oseltamivir can reduce the proportion of symptomatic influenza in prevention research.It can shorten the time needed for symptom relief in treatment research; However, there is no obvious effect in improving the hospitalization rate, and there is no strong evidence to support the reduction of influenza complications such as pneumonia, which has no obvious effect in reducing the spread of the virus. At the same time, it also questioned the practice of many countries in the world to reserve Tamiflu to prevent influenza pandemic.

In response to these reports, Roche issued a statement saying that it disagreed with the overall conclusion of Cochrane Collaboration Group. This report did not include all the data about Tamiflu, "only included 20 research data from 77 clinical trials they had mastered, and excluded the actual data obtained from observational trials".

However, in 2017, WHO adjusted Tamiflu from "core drug" in the list of essential drugs to "supplementary drug", and the applicable population was hospitalized critically ill patients who were diagnosed or suspected of influenza.

Although many doctors are skeptical about Tamiflu, they are like Paul Fenyves Similarly, they can’t ignore a drug that may be helpful to patients, especially the drug approved by the US Centers for Disease Control and Prevention. Therefore, doctors continue to prescribe Tamiflu to patients with high-risk influenza, hoping that the advantages outweigh the disadvantages.

Paxlovid’s data

Paxlovid’s situation is not exactly the same as Tamiflu’s, but there must be some "historical reappearance": doctors have to make clinical decisions on antiviral drugs for respiratory viruses without sufficient data.

There are two noteworthy facts about the people who participated in the Paxlovid trial. They were not vaccinated with Covid-19 vaccine and had never been infected with Covid-19 before.

First of all, even if the Paxlovid trial began in July 2021, only a few Americans were in the category of unvaccinated and uninfected with Covid-19, so the test results were never directly applicable to most Americans.

Secondly, Paxlovid is obviously more effective for people who have not been vaccinated with COVID-19 vaccine or have never been infected before, so the experiments supporting its use exaggerate the benefits that most people see from the drug.

Maybe you will say that Pfizer has started to test Paxlovid in high-risk population who have been vaccinated with COVID-19 vaccine, yes, but this trial is a mixture of vaccinated and unvaccinated patients, which may confuse the problem. More importantly, the test results will not be released until November 2022.

On April 29th, Pfizer released a phase II/III clinical (EPIC-PEP) study of Paxlovid for post-exposure prevention. The results show that,Paxlovid failed to reach the main end point, that is, effectively preventing the infection of family members who had contact with confirmed patients in COVID-19.. Therefore, Paxlovid has no preventive effect.

Who cares?

Pfizer’s first experiment exaggerated the efficacy of Paxlovid, which is not surprising, because as a pharmaceutical company, it has endless motivation to maximize its influence and promote sales.

But to everyone’s surprise, the US federal government will buy Paxlovid worth $5 billion, without Pfizer’s quick action to answer this basic question: "How does Paxlovid perform in high-risk groups who have been vaccinated with COVID-19 vaccine or previously infected?"

Paxlovid costs $530 (about 3,500 yuan) for a five-day course of treatment, but if there is no proper data, it is impossible to judge whether it is a good deal or a bad one. For example, if it is necessary to prescribe 10,000 courses of Paxlovid for people over 65 who have been vaccinated with COVID-19 vaccine to prevent one hospitalization, then a government may not place an order immediately; On the contrary, if 10 people can avoid a hospitalization by taking Paxlovid, they will be in a hurry to buy more.

However, if we don’t know the performance of Paxlovid in people who have been vaccinated with COVID-19 vaccine, it is impossible to make such calculations.

In addition, given the history of Tamiflu, the requirements for data transparency and independent review should be cautious.

Some people may say, even if we finally learn that Paxlovid’s benefits from people who have been vaccinated or infected before are greatly weakened, who cares?

But this problem is a symbol of a bigger problem: we lack the much-needed independent review of drug clinical trials.

Americans have seen scandals caused by poor supervision. When Covid-19 appeared, the pharmaceutical industry performed exceptionally well, providing safe and effective vaccines in record time. But before that, many Americans had "learned" not to trust Big Pharma, so many people (tragically) rejected this life-saving intervention.

Comparison of Action Mechanism between COVID-19 Vaccine and Oral Medicine

The discussion around "vaccine indecision" mainly focuses on false information, but what is missing is to admit that the pharmaceutical industry has wasted public trust for decades.

Instead of continuing to feel depressed about people who have not been vaccinated, we should reflect on ourselves and then start rebuilding the public’s trust step by step, which will be a long-term work.